Absci Corp., a generative AI antibody discovery firm, entered a collaboration with AstraZeneca to deliver an AI-designed antibody against an oncology target. The collaboration will leverage Absci’s Integrated Drug Creation platform and AstraZeneca’s expertise in oncology with the goal of accelerating the discovery of a potential new cancer treatment candidate.
 
Absci will contribute generative AI technology to deliver a therapeutic candidate antibody for a specified oncology target. The agreement includes an upfront commitment, R&D funding and milestone payments, in addition to royalties on product sales.
 
“AstraZeneca is a leader in developing novel treatments in oncology, and we are excited to collaborate with them to design a therapeutic candidate antibody with the potential to improve the lives of cancer patients,” said Sean McClain, Absci Founder & CEO. “This agreement advances Absci’s goal of creating a new generation of life-changing and transformative therapeutics using its AI platform.”
 
Puja Sapra, Ph.D., Senior Vice President of Biologics Engineering & Oncology Targeted Delivery, AstraZeneca said, “This collaboration is an exciting opportunity to utilize Absci’s de novo AI antibody creation platform to design a potential new antibody therapy in oncology.”